Halozyme Therapeutics (HALO) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to 0.02.
- Halozyme Therapeutics' Equity Ratio fell 8903.67% to 0.02 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.02, marking a year-over-year decrease of 8903.67%. This contributed to the annual value of 0.02 for FY2025, which is 8903.67% down from last year.
- Per Halozyme Therapeutics' latest filing, its Equity Ratio stood at 0.02 for Q4 2025, which was down 8903.67% from 0.23 recorded in Q3 2025.
- Halozyme Therapeutics' Equity Ratio's 5-year high stood at 0.24 during Q3 2021, with a 5-year trough of 0.02 in Q4 2025.
- In the last 5 years, Halozyme Therapeutics' Equity Ratio had a median value of 0.14 in 2024 and averaged 0.13.
- In the last 5 years, Halozyme Therapeutics' Equity Ratio skyrocketed by 26464.38% in 2024 and then plummeted by 8903.67% in 2025.
- Over the past 5 years, Halozyme Therapeutics' Equity Ratio (Quarter) stood at 0.18 in 2021, then tumbled by 48.29% to 0.09 in 2022, then plummeted by 47.56% to 0.05 in 2023, then skyrocketed by 264.64% to 0.18 in 2024, then crashed by 89.04% to 0.02 in 2025.
- Its Equity Ratio stands at 0.02 for Q4 2025, versus 0.23 for Q3 2025 and 0.16 for Q2 2025.